Vir Biotechnology (VIR) Debt Ratio (2019 - 2025)

Vir Biotechnology's (VIR) quarterly Debt Ratio came in at 0.01 in Q1 2025, up 16.56% quarter-over-quarter from 0.01 in Q4 2024.

Vir Biotechnology (VIR) Debt Ratio (2019 - 2025) Analysis & Trends

Vir Biotechnology has disclosed Debt Ratio across 5 years of filings, most recently posting 0.01 for Q1 2025.

  • Debt Ratio for Q1 2025 came in at 0.01, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was 0.01 (changed N/A YoY), and the FY2024 annual result was 0.01, changed N/A from the prior year.
  • Debt Ratio came in at 0.01 for Q1 2025 at Vir Biotechnology, up from 0.01 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.06 in Q3 2021 to a low of 0.01 in Q4 2024.
  • The 3-year median for Debt Ratio is 0.02 (2021), against an average of 0.03.
  • Peak annual rise in Debt Ratio reached 254.33% in 2021, while the deepest fall reached 4.19% in 2021.
  • Vir Biotechnology's Debt Ratio stood at 0.06 in 2021, then plunged by 79.72% to 0.01 in 2024, then rose by 16.56% to 0.01 in 2025.
  • The last three Debt Ratio figures came in at 0.01 (Q1 2025), 0.01 (Q4 2024), and 0.06 (Q3 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.18
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Vir Biotechnology 1.35 Bn 1.35 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 0.01
Dec 31, 2024 0.01
Sep 30, 2021 0.06
Jun 30, 2021 0.02
Mar 31, 2021 0.02
Dec 31, 2020 0.01
Sep 30, 2020 0.02
Jun 30, 2020 0.01
Mar 31, 2020 0.02
Dec 31, 2019 0.02
Sep 30, 2019 0.02